# A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

> **NCT01288209** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 106 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** TMC435
- **DRUG:** Peginterferon alfa-2a (PegIFNα-2a )
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT01288209
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2014-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288209, "A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01288209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*